Please assess the completion status of the following clinical trial:

Trial Title: PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed metastatic and/or recurrent Squamous Cell Carcinoma of Head and Neck (SCCHN) determined to be incurable by surgery and/or radiation therapy.~* Measurable disease by CT scan~* Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1~* Age: 18 years or older~* Adequate hematologic, renal, metabolic, hepatic \& thyroid function~Exclusion Criteria:~* Prior systemic treatment for metastatic and/or recurrent SCCHN~* CNS metastases, or nasopharyngeal carcinoma~* History of interstitial lung disease~* History of another primary cancer~* Any co-morbid disease that would increase risk of toxicity~  * Active infection requiring systemic treatment~ * Prior anti-Epidermal Growth Factor receptor (anti-EGFr) antibody therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Panitumumab + Docetaxel + Cisplatin
- Arm 2 (Type: OTHER): control

Based on this trial design, predict the completion outcome and termination type (if applicable).